OACC vs GH vs EXAS vs RLAY vs ILMN

For growth investors, Relay Therapeutics, Inc.

(RLAY) is the stronger pick with 53. 4% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Illumina, Inc. (ILMN) offers the better valuation at 26. 0x trailing P/E (27. 2x forward), making it the more compelling value choice. Analysts rate Guardant Health, Inc. (GH) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Illumina, Inc.

(ILMN) is the cheapest at 26. 0x versus Oaktree Acquisition Corp. III Life Sciences at 197. 4x. On forward P/E, Illumina, Inc. is actually cheaper at 27. 2x.

Over the past 5 years, Oaktree Acquisition Corp.

III Life Sciences (OACC) delivered a total return of +7. 0%, compared to -61. 6% for Illumina, Inc. (ILMN). Over 10 years, the gap is even starker: EXAS returned +1669% versus RLAY's -63. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus Relay Therapeutics, Inc. 's 1. 77β — meaning RLAY is approximately 3260% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Oaktree Acquisition Corp. III Life Sciences (OACC) carries a lower debt/equity ratio of 0% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Relay Therapeutics, Inc.

(RLAY) is pulling ahead at 53. 4% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to 6. 7% for Guardant Health, Inc.. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — RLAY leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Illumina, Inc.

(ILMN) trades at 27. 2x forward P/E versus 582. 8x for Exact Sciences Corporation — 555. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RLAY: 69. 3% to $21. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). Relay Therapeutics, Inc. (RLAY) carries a higher beta of 1. 77 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, RLAY: -63. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OACC (Financial Services) and GH (Healthcare) and EXAS (Healthcare) and RLAY (Healthcare) and ILMN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OACC is a small-cap quality compounder stock; GH is a mid-cap high-growth stock; EXAS is a mid-cap high-growth stock; RLAY is a small-cap high-growth stock; ILMN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.